期刊： PHARMACOECONOMICS, 2022; 40 (7)
Background and Objective A new gastric cancer screening scoring system (NGCS) strategy was recommended for the early gastric cancer (GC) screening pro......
期刊： PHARMACOECONOMICS, 2022; 40 (12)
Objective The aim of this study was to model the potential long-term disease progression and pharmacoeconomic value of sacubitril/valsartan for the tr......
期刊： PHARMACOECONOMICS, 2022; 40 (7)
Background High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. Since 2017, China ha......
期刊： PHARMACOECONOMICS, 2022; 40 (10)
Background and Objectives Existing generic preference-based measures were all developed in Western countries. Evidence shows that the Chinese populati......
期刊： PHARMACOECONOMICS, 2022; 40 (SUPPL 2)
Introduction The standard EQ-5D-Y-3L valuation protocol applies DCE data as the primary preference source to model the relative importance of dimensio......
期刊： PHARMACOECONOMICS, 2021; 39 (7)
The availability and use of tools to guide the choice of modelling technique are not well understood. Our study aims to review existing tools and expl......
Objectives Our objective was to generate a value set for the SF-6Dv2 using time trade-off (TTO) and a discrete-choice experiment with a duration dimen......
期刊： PHARMACOECONOMICS, 2020; 38 (12)
Background Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions a......
期刊： PHARMACOECONOMICS, 2020; 38 (12)
Background Patients with moderate-to-severe rheumatoid arthritis have a heavy financial burden. The cost-effectiveness of introducing tofacitinib to t......
期刊： PHARMACOECONOMICS, 2019; 37 (3)
BackgroundThe economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011.ObjectiveThe ob......
期刊： PHARMACOECONOMICS, 2019; 37 (6)
Background and ObjectivePopulation-level endoscopic screening for esophageal cancer has been conducted in China for years. In this study, we aim to pr......
期刊： PHARMACOECONOMICS, 2019; 37 (12)
Background The influx of new oncologic technologies has changed the treatment landscape of renal cell carcincoma (RCC) in the last decade. This study ......
期刊： PHARMACOECONOMICS, 2018; 36 (8)
Background The overuse of antibiotics has become a major public health challenge worldwide, especially in low- and middle-income countries, including ......
